LBA11 IMpassion031: Results from a phase III study of neoadjuvant (neoadj) atezolizumab + chemotherapy in early triple-negative breast cancer (TNBC)

Harbeck, Nadia; Zhang, H.; Barrios, Carlos H.; Jung, Kyung Hae; Hegg, Roberto; Koehler, Andreas; Sohn, Joohyuk; Iwata, Hiroji; Telli, Melinda L.; Ferrario, Cristiano; Punie, Kevin; Penault‐Llorca, Frédérique; Patel, Shilpen; Duc, Anh Nguyen; Liste-Hermoso, Mario; Maiya, Vidya; Molinero, Luciana; Chui, Sy; Mittendorf, EA

doi:10.1016/j.annonc.2020.08.2239

Cited by 21 publications

(31 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Similar results have now been reported with atezolizumab 13 . The IMpassion031 study included patients with early TNBC whose primary tumour was at least 2 cm in size.…”

Section: Neoadjuvant Therapysupporting

confidence: 90%

“…No new side-effect profiles were reported. Thus, in the neoadjuvant setting in TNBC, two randomised trials, one on pembrolizumab 11 and the other on atezolizumab 13 , have now shown a significant improvement in pCR rate.…”

Section: Neoadjuvant Therapymentioning

confidence: 99%

“…In der Subgruppenanalyse nach PD-L1-Status (positiv, wenn mindestens 1% der Immunzellen eine Färbung zeigten) konnten in der Gruppe mit positivem PD-L1-Status pCR-Raten von 68,8% (Atezolizumab-Arm) und 49,3% (Placeboarm) nachgewiesen werden (Unterschied 19,5%, 95%-KI: 4,2 – 34,8%). Bei den Patientinnen mit PD-L1-negativem Mammakarzinom konnten pCR-Raten von 47,4% (Atezolizumab-Arm) und 34,4% (Placeboarm) erreicht werden (Differenz 13,3%; 95%-KI: − 0,9 – 27,5%) 13 . Auch die Überlebensparameter (ereignisfreies Überleben, krankheitsfreies Überleben und Gesamtüberleben) wurden mit einer medianen Beobachtungszeit von ca.…”

Section: Immuntherapien In Der Neoadjuvanzunclassified

“…Keine neuen Nebenwirkungsprofile wurden berichtet. Somit gibt es in der neoadjuvanten Situation bei den TNBC nun 2 randomisierte Studien, eine mit Pembrolizumab 11 und eine mit Atezolizumab 13 , die eine signifikante Verbesserung der pCR-Rate zeigen.…”

Section: Immuntherapien In Der Neoadjuvanzunclassified

See 3 more Smart Citations

Update Breast Cancer 2020 Part 5 – Moving Therapies From Advanced to Early Breast Cancer Patients

Lux

Schneeweiß

Hartkopf

et al. 2021

Geburtshilfe Frauenheilkd

View full text Add to dashboard Cite

In recent years, significant progress has been made in new therapeutic approaches to breast cancer, particularly in patients with HER2-positive and HER2-negative/hormone receptor-positive (HR+) breast cancer. In the case of HER2-positive tumours, these approaches have included, in particular, treatment with pertuzumab, T-DM1, neratinib and, soon, also tucatinib and trastuzumab deruxtecan (neither of which has yet been authorised in Europe). In patients with HER2−/HR+ breast cancer, CDK4/6 inhibitors and the PIK3CA inhibitor alpelisib are of particular importance. Further novel therapies, such as Akt kinase inhibitors and oral SERDs (selective estrogen receptor down regulators), are already being investigated in ongoing clinical trials. These therapeutic agents are not only being introduced into curative, (neo-)adjuvant therapeutic settings for HER2-positive tumours; a first favourable study on abemaciclib as an adjuvant therapy has now also been published. In patients with triple-negative breast cancer, after many years of negative study results with the Trop-2 antibody drug conjugate (ADC) sacituzumab govitecan, a randomised study has been published that may represent a significant therapeutic advance. This review describes the latest developments in breast cancer subsequent to the ESMO Congress 2020.

show abstract

“…Similar results have now been reported with atezolizumab 13 . The IMpassion031 study included patients with early TNBC whose primary tumour was at least 2 cm in size.…”

Section: Neoadjuvant Therapysupporting

confidence: 90%

Section: Neoadjuvant Therapymentioning

confidence: 99%

Section: Immuntherapien In Der Neoadjuvanzunclassified

See 2 more Smart Citations

Update Breast Cancer 2020 Part 5 – Moving Therapies From Advanced to Early Breast Cancer Patients

Lux

Schneeweiß

Hartkopf

et al. 2021

Geburtshilfe Frauenheilkd

View full text Add to dashboard Cite

show abstract

“…Second, a significant improvement in pCR rate was recently reported when pembrolizumab was added to NACT (carboplatin/paclitaxel followed by AC) in non-metastatic TNBC, while preliminary analysis suggested a possible and promising advantage in event-free survival (72,73). A similar improvement in pCR was recently demonstrated with atezolizumab when combined with anthracyclines/taxanes but carboplatin-free NACT in IMpassion 031 trial (74). Yet, results from other studies evaluating anti-PD-L1 antibodies such as durvalumab, another anti-PD-L1 antibody in combination with anthracyclines/taxanes (75), or atezolizumab in combination with anthracyclines-free regimen (NeoTripp trial: NCT002620280) NACT in TNBC failed to significantly improve pCR rates (76).…”

Section: Pembrolizumab and Other Anti-pd1/pd-l1 Agents In Bcmentioning

confidence: 76%

PELICAN-IPC 2015-016/Oncodistinct-003: A Prospective, Multicenter, Open-Label, Randomized, Non-Comparative, Phase II Study of Pembrolizumab in Combination With Neo Adjuvant EC-Paclitaxel Regimen in HER2-Negative Inflammatory Breast Cancer

Bertucci

Zemmour

et al. 2020

Front. Oncol.

View full text Add to dashboard Cite

Inflammatory breast cancer (IBC) is a highly aggressive entity with a poor outcome and relative resistance to treatment. Despite progresses achieved during the last decades, the survival remains significantly lower than non-IBC. Recent clinical trials assessing PD-1/PD-L1 inhibitors showed promising results in non-IBC. Pembrolizumab, an anti-PD-1 monoclonal antibody, revolutionized the treatment of different cancers. Several recent studies suggested a potential interest of targeting the immune system in IBC by revealing a more frequent PD-L1 expression and an enriched immune microenvironment when compared with non-IBC. Here, we describe the rationale and design of PELICAN-IPC 2015-016/Oncodistinct-003 trial, an open-label, randomized, non-comparative, phase II study assessing efficacy, and safety of pembrolizumab in combination with anthracycline-containing neoadjuvant chemotherapy in HER2-negative IBC. The trial is ongoing. The primary endpoint is the pCR rate (ypT0/Tis, ypN0) in overall population and the co-primary endpoint is safety profile during a run-in phase. Key secondary objectives include tolerability, invasive disease-free, event-free and overall survivals, as well as collection of tumor and blood samples for translational research.Clinical Trial Registrationhttps://clinicaltrials.gov/ (NCT03515798).

show abstract

CDK4/6 inhibitors: A potential therapeutic approach for triple negative breast cancer

Saleh

Wilson

Holen

2021

MedComm

View full text Add to dashboard Cite

Triple negative breast cancer (TNBC) cells lack expression of the estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor‐2 (HER‐2). Thus, TNBC does not respond to hormone‐based therapy. TNBC is also an aggressive subtype associated with poorer prognoses compared to other breast cancers. Conventional chemotherapeutics are used to manage TNBC although systemic relapse is common with limited benefits being reported as well as adverse events being documented. Here, we discuss current therapies for TNBC in the neo‐ and adjuvant settings, as well as recent advancements in the targeting of PD‐L1‐positive tumors and inclusion of PARP inhibitors for TNBC patients with BRCA mutations. The recent development of cyclin‐dependent kinase (CDK) 4/6 inhibitors in ER‐positive breast cancers has demonstrated significant improvements in progression free survival in patients. Here, we review preclinical data of CDK 4/6 inhibitors and describe current clinical trials assessing these in TNBC disease.

show abstract

LBA11 IMpassion031: Results from a phase III study of neoadjuvant (neoadj) atezolizumab + chemotherapy in early triple-negative breast cancer (TNBC)

Cited by 21 publications

References 0 publications

Update Breast Cancer 2020 Part 5 – Moving Therapies From Advanced to Early Breast Cancer Patients

Update Breast Cancer 2020 Part 5 – Moving Therapies From Advanced to Early Breast Cancer Patients

PELICAN-IPC 2015-016/Oncodistinct-003: A Prospective, Multicenter, Open-Label, Randomized, Non-Comparative, Phase II Study of Pembrolizumab in Combination With Neo Adjuvant EC-Paclitaxel Regimen in HER2-Negative Inflammatory Breast Cancer

CDK4/6 inhibitors: A potential therapeutic approach for triple negative breast cancer

Contact Info

Product

Resources

About